Multidisciplinary treatment of a patient with severe immune checkpoint inhibitor-induced colitis: A case report

BACKGROUND: Immune checkpoint inhibitors (ICIs) are a new class of antitumor drugs that have been approved to treat a variety of malignant tumors. However, the occurrence of immune related adverse events (irAEs) has become an important reason for terminating treatment. ICIs sometimes lead to diarrhe...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Lu, Sha, Li, Feng, Yu, Yan, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782922/
https://www.ncbi.nlm.nih.gov/pubmed/36569020
http://dx.doi.org/10.12998/wjcc.v10.i35.13108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782922/
https://www.ncbi.nlm.nih.gov/pubmed/36569020
http://dx.doi.org/10.12998/wjcc.v10.i35.13108

Ejemplares similares